Boehringer Ingelheim Prolongates Drug Discovery Collaboration with Priaxon
The companies will continue working jointly to identify and advance drug candidates into pre-clinical development. Thereafter, Boehringer Ingelheim will drive the development and commercialisation of the potential cancer treatments arising from the collaboration.
"Priaxon has been able to develop promising mdm2/p53 inhibitors with its PriaXplore® technology", said Dr Juergen Kolb, CEO of Priaxon. "We are proud that Boehringer Ingelheim appreciates Priaxon as a competent partner by prolongating the collaboration to advance the high potency lead compounds. We enjoy the fair and creative atmosphere of this cooperation very much."
Priaxon is entitled to up to EUR 86 million in milestone payments upon achievement of certain development, regulatory and commercial milestones as well as royalties on potential future net sales of products.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.